Skip to main content
. Author manuscript; available in PMC: 2012 Oct 9.
Published in final edited form as: Nat Med. 2011 Dec 11;18(1):74–82. doi: 10.1038/nm.2577

Figure 3. Gefitinib downregulates miR-221-222 and 30b-c.

Figure 3

(a) Calu-1, A549, PC9 and Hcc827 cells were treated with increasing concentrations of gefitinib. Cell viability, relative to untreated controls, was measured after 24h. Each data point represents the mean ± s.d. of five wells. (b) qRT-PCR showing miR-30b-c and -221-222 down-regulation only in PC9 and Hcc827 gefitinib-sensitive cells and not in Calu-1 and A549-resistant cells after treatment with 5 or 10 μM gefitinib. (c) PC9, Calu-1 and Hcc827 cells were treated for 24h with 5 or 10 μM gefitinib. An increase of BIM and APAF-1 expression and a decrease of ERKs phosphorylation were observed only in the Hcc827 and PC9 gefitinib-sensitive cells but not in the Calu-1 -resistant cells. β-actin was used as loading control. (d) qRT-PCR showing that miR-30b-c and -221-222 expression did not decrease in PC9 GR and HCC827GR cells (with acquired gefitinib resistance) exposed to 10 μM gefitinib for 24h. All quantitative data were generated from a minimum of three replicates. Error bars depict ± s.d. Two tailed student's t test was used to determine P values. *P<0.001, **P<0.05.